Although our current approach is designed to produce a full-length antibody to directly target immune cells with IgG1 and IgG4 options, our platform can be used to deliver other forms of mAbs such as single-chain mAbs (scFv) or any mAb with diverse functions such as T-cell checkpoint blockade including anti-PD1, anti-PD-L1, anti-CTL4 or mAbs that directly target tumor cells, e.g., the anti-EGFR mAb52,53. The gene discussed is EGFR; the disease is neoplasm.